AR057377A1 - Derivados de cicloheptapiridina como inhibidores de tirosina quinasa. composiciones farmaceuticas - Google Patents
Derivados de cicloheptapiridina como inhibidores de tirosina quinasa. composiciones farmaceuticasInfo
- Publication number
- AR057377A1 AR057377A1 ARP060102571A ARP060102571A AR057377A1 AR 057377 A1 AR057377 A1 AR 057377A1 AR P060102571 A ARP060102571 A AR P060102571A AR P060102571 A ARP060102571 A AR P060102571A AR 057377 A1 AR057377 A1 AR 057377A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heterocyclyl
- alkenyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a derivados de 5H-benzo[4,5]ciclohepta[1,2-b]piridina, que son utiles para tratar enfermedades proliferativas celulares, para tratar trastornos asociados con actividad de MET, y para inhibir la tirosina quinasa de receptor MET. La presente también se refiere a composiciones que comprenden estos compuestos, y a procedimientos para usarlos para tratar el cáncer en mamíferos. Reivindicacion 1: Un compuesto de formula (1), o una sal o estereoisomero farmacéuticamente aceptable del mismo, en la que una línea discontinua representa un doble enlace opcional; a es independientemente 0 o 1; b es independientemente 0 o 1; m es independientemente 0, 1, o 2; Rl se selecciona entre arilo, heterociclilo y NR10R11; estando dicho grupo arilo y heterociclilo opcionalmente sustituido con uno a cinco sustituyentes, cada sustituyente seleccionado independientemente entre R8; R5 se selecciona entre hidrogeno, alquilo C1-6, alquenilo C2-6, OH, -O-alquilo C1-6, -O- C(=O)alquiloC1-6, -O-arilo, S(O)mRa, -C(=O)NRl0R11, -NHS(O)2NR10R11 y NRl0R11, estando cada grupo alquilo, alquenilo y arilo opcionalmente sustituido con uno a cinco sustituyentes, cada sustituyente seleccionado independientemente entre R8; R8 independencia es: (C=O)aObalquiloC1-10, (C=O)aObarilo, alquenilo C2-C10, alquinilo C2-C10, (C=O)aObheterociclilo, CO2H, halo, CN, OH, ObperfluoroalquiloC1-6, Oa(C=O)bNRl0Rll, S(O)mRa, S(O)2NRl0R11, OS(=O)Ra, oxo, CHO, (N=O)R10R11, o (C=O)aObcicloalquiloC3-8, estando dichos grupos alquilo, arilo, alquenilo, alquinilo, heterociclilo, y cicloalquilo opcionalmente sustituido con uno, dos o tres sustituyentes seleccionado entre R9; R9 se selecciona independientemente entre: (C=O)aObalquiloC1-10, ObperfluoroalquiloC1-3, oxo, OH, halo, CN, alquenilo C2-10, alquinilo C2-10, (C=O)aObcicloalquiloC3-6, (C=O)aObalquilenC0-6-arilo, (C=O)aObalquilenC0-6-heterociclilo, (C=O)aObalquilenC0-6-N(Rb)2, C(O)Ra, alqulenC0-6-CO2Ra, C(O)H, alquilenC0-6-CO2H, C(O)N(Rb)2, S(O)mRa, y S(O)2NR10R11; estando dichos grupos alquilo, alquenilo, alquinilo, cicloalquilo, arilo, y heterociclilo opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados entre Rb, OH, alcoxi C1-6, halogeno, CO2H, CN, O(C=O)alquiloC1-6, oxo, y N(Rb)2; R10 y R11 se seleccionan independientemente entre: H, (C=O)ObalquiloC1-10, (C=O)ObcicloalquiloC3-8, (C=O)Obarilo, (C=O)Obheterociclilo, alquilo C1-10, arilo, alquenilo C2-10, alquinilo C2- 10, heterociclilo, cicloalquilo C3-8, SO2Ra, y (C=O)NRb2, estando dichos grupos alquilo, cicloalquilo, arilo, heterociclilo, alquenilo, y alquinilo opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados entre R8; o R10 y R11 pueden tomarse junto con el nitrogeno al que están unidos para formar un heterociclo monocíclico o bicíclico con 5-7 miembros en cada anillo y conteniendo opcionalmente, además del nitrogeno, uno o dos heteroátomos adicionales seleccionados entre N, O y S, estando dicho heterociclo monocíclico o bicíclico opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados entre R9; Ra se selecciona independientemente entre: alquilo C1-6, alquenilo C2-6, cicloalquilo C3-6, arilo, - alquilenC1-6-arilo, heterociclilo y -alquilenC1-6-heterociclilo; y Rb se selecciona independientemente entre: H, alquilo C1-6, arilo, -alquilenC1-6arilo, heterociclilo, -alquilenC1-6-heterociclilo, cicloalquilo C3-6, (C=O)OalquiloC1-6, (C=O)alquiloC1-6 o S(O)2Ra.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69322905P | 2005-06-23 | 2005-06-23 | |
| US72906105P | 2005-10-21 | 2005-10-21 | |
| US78947306P | 2006-04-05 | 2006-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057377A1 true AR057377A1 (es) | 2007-11-28 |
Family
ID=37595817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102571A AR057377A1 (es) | 2005-06-23 | 2006-06-16 | Derivados de cicloheptapiridina como inhibidores de tirosina quinasa. composiciones farmaceuticas |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1896422B1 (es) |
| KR (1) | KR20080018907A (es) |
| AR (1) | AR057377A1 (es) |
| AT (1) | ATE520664T1 (es) |
| BR (1) | BRPI0612518A2 (es) |
| CR (1) | CR9579A (es) |
| CY (1) | CY1112038T1 (es) |
| DO (1) | DOP2006000143A (es) |
| EC (1) | ECSP078017A (es) |
| IL (1) | IL187895A0 (es) |
| MA (1) | MA29643B1 (es) |
| MX (1) | MX2007016533A (es) |
| NI (1) | NI200700318A (es) |
| NO (1) | NO20080417L (es) |
| NZ (1) | NZ563711A (es) |
| PE (1) | PE20070167A1 (es) |
| PL (1) | PL1896422T3 (es) |
| PT (1) | PT1896422E (es) |
| SI (1) | SI1896422T1 (es) |
| TW (1) | TW200738638A (es) |
| WO (1) | WO2007002258A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200813021A (en) * | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
| US7893081B2 (en) * | 2007-12-20 | 2011-02-22 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP2482803B1 (en) | 2009-09-30 | 2021-12-22 | Merck Sharp & Dohme (UK) Limited | Formulations for c-met kinase inhibitors |
| CA2771338A1 (en) | 2009-09-30 | 2011-04-07 | Merck Sharp & Dohme Corp. | Crystalline hydrochloride salts of c-met kinase inhibitors |
| EP2588107A1 (en) | 2010-07-01 | 2013-05-08 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE363473T1 (de) * | 2001-09-19 | 2007-06-15 | Pharmacia Corp | Substituierte pyrazoloverbindungen zur behandlung von entzündungen |
| WO2003084931A1 (en) * | 2002-04-02 | 2003-10-16 | Merck & Co., Inc. | 5h-benzo[4,5]cyclohepta[1,2-b]pyridine nmda/nr2b antagonists |
-
2006
- 2006-06-14 TW TW095121232A patent/TW200738638A/zh unknown
- 2006-06-16 AR ARP060102571A patent/AR057377A1/es not_active Application Discontinuation
- 2006-06-21 PE PE2006000702A patent/PE20070167A1/es not_active Application Discontinuation
- 2006-06-22 EP EP06785319A patent/EP1896422B1/en active Active
- 2006-06-22 AT AT06785319T patent/ATE520664T1/de active
- 2006-06-22 WO PCT/US2006/024256 patent/WO2007002258A2/en not_active Ceased
- 2006-06-22 PT PT06785319T patent/PT1896422E/pt unknown
- 2006-06-22 BR BRPI0612518-2A patent/BRPI0612518A2/pt not_active IP Right Cessation
- 2006-06-22 KR KR1020077030202A patent/KR20080018907A/ko not_active Withdrawn
- 2006-06-22 PL PL06785319T patent/PL1896422T3/pl unknown
- 2006-06-22 SI SI200631136T patent/SI1896422T1/sl unknown
- 2006-06-22 MX MX2007016533A patent/MX2007016533A/es unknown
- 2006-06-22 NZ NZ563711A patent/NZ563711A/en not_active IP Right Cessation
- 2006-06-23 DO DO2006000143A patent/DOP2006000143A/es unknown
-
2007
- 2007-12-04 NI NI200700318A patent/NI200700318A/es unknown
- 2007-12-04 IL IL187895A patent/IL187895A0/en unknown
- 2007-12-07 CR CR9579A patent/CR9579A/es not_active Application Discontinuation
- 2007-12-14 EC EC2007008017A patent/ECSP078017A/es unknown
-
2008
- 2008-01-22 NO NO20080417A patent/NO20080417L/no not_active Application Discontinuation
- 2008-01-23 MA MA30591A patent/MA29643B1/fr unknown
-
2011
- 2011-11-16 CY CY20111101099T patent/CY1112038T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR9579A (es) | 2008-03-06 |
| PL1896422T3 (pl) | 2012-01-31 |
| CY1112038T1 (el) | 2015-11-04 |
| EP1896422B1 (en) | 2011-08-17 |
| BRPI0612518A2 (pt) | 2010-11-23 |
| ATE520664T1 (de) | 2011-09-15 |
| MA29643B1 (fr) | 2008-07-01 |
| NZ563711A (en) | 2010-12-24 |
| EP1896422A2 (en) | 2008-03-12 |
| WO2007002258A2 (en) | 2007-01-04 |
| PE20070167A1 (es) | 2007-04-16 |
| IL187895A0 (en) | 2008-03-20 |
| ECSP078017A (es) | 2008-01-23 |
| NI200700318A (es) | 2008-05-23 |
| MX2007016533A (es) | 2008-03-06 |
| KR20080018907A (ko) | 2008-02-28 |
| PT1896422E (pt) | 2011-11-08 |
| SI1896422T1 (sl) | 2011-11-30 |
| NO20080417L (no) | 2008-03-18 |
| DOP2006000143A (es) | 2007-02-28 |
| WO2007002258A3 (en) | 2007-06-07 |
| TW200738638A (en) | 2007-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061804A1 (es) | Inhibidores de tirosina quinasa | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| CL2019002167A1 (es) | Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.) | |
| AR062360A1 (es) | Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa | |
| PE20250021A1 (es) | Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 | |
| AR044543A1 (es) | Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
| AR119018A1 (es) | Inhibidores de proteína quinasas dependientes de adn | |
| EA201792394A3 (ru) | Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака | |
| AR059905A1 (es) | Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto | |
| AR113299A1 (es) | Compuestos de isoindolina | |
| AR055630A1 (es) | Derivados de diazaspiro como antagonistas del receptor ccr8, un proceso para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades respiratorias. | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR060875A1 (es) | Derivados de 2-piridona como inhibidores de la neutrofilo elastasa humana | |
| AR070429A1 (es) | Derivados de 1,3 tiazol como inhibidores de estearoil - coa -desaturasa | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
| AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
| AR091490A1 (es) | Antagonistas de iap | |
| AR057377A1 (es) | Derivados de cicloheptapiridina como inhibidores de tirosina quinasa. composiciones farmaceuticas | |
| AR071300A1 (es) | Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento | |
| BR112012028992A2 (pt) | 1 - [(4-hidroxipiredina-4-il)metil]piridina-2 (1h) -ona, método de preparação e utilização dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |